- Home
- SAN vs SNY Comparison
SAN vs SNY Comparison
Compare SAN & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAN
- SNY
- Stock Information
- Founded
- SAN 1857
- SNY 1994
- Country
- SAN Spain
- SNY France
- Employees
- SAN N/A
- SNY N/A
- Industry
- SAN Commercial Banks
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- SAN Finance
- SNY Health Care
- Exchange
- SAN Nasdaq
- SNY Nasdaq
- Market Cap
- SAN 112.2B
- SNY 127.2B
- IPO Year
- SAN 1987
- SNY N/A
- Fundamental
- Price
- SAN $7.91
- SNY $49.19
- Analyst Decision
- SAN
- SNY Buy
- Analyst Count
- SAN 0
- SNY 2
- Target Price
- SAN N/A
- SNY $62.50
- AVG Volume (30 Days)
- SAN 4.8M
- SNY 2.4M
- Earning Date
- SAN 07-23-2025
- SNY 07-24-2025
- Dividend Yield
- SAN 3.10%
- SNY 4.50%
- EPS Growth
- SAN 20.30
- SNY 39.56
- EPS
- SAN 0.87
- SNY 5.45
- Revenue
- SAN $54,835,711,180.00
- SNY $48,817,552,946.00
- Revenue This Year
- SAN $23.44
- SNY $3.39
- Revenue Next Year
- SAN $2.47
- SNY $7.05
- P/E Ratio
- SAN $9.05
- SNY $9.02
- Revenue Growth
- SAN 6.36
- SNY N/A
- 52 Week Low
- SAN $4.27
- SNY $45.80
- 52 Week High
- SAN $8.08
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- SAN 63.44
- SNY 37.66
- Support Level
- SAN $7.89
- SNY $48.59
- Resistance Level
- SAN $8.06
- SNY $52.41
- Average True Range (ATR)
- SAN 0.11
- SNY 0.77
- MACD
- SAN -0.02
- SNY -0.25
- Stochastic Oscillator
- SAN 62.77
- SNY 12.58
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.